The Hardest Part of Life Science Isn't the Science

The hardest problem in life science isn't the science. It's the 18 months after the science works.

I've watched it happen to company after company. The technology is real. The data is strong. The round closed. And then progress stalls quietly somewhere between "it works" and "someone is actually using it." The team is just as brilliant as it was a year ago, but the pipeline is thin, the first customers are taking far longer than planned, and the next raise is getting closer.

It's rarely a product problem. It's a foundation problem.

Why great science stalls on the way to market

Most life science and health-tech companies are built by people who are exceptional at discovery. That's exactly right for the first chapter. But the skills that get a product to work are different from the skills that get a hospital, lab, or pharma team to buy it, and the gap usually shows up at the worst moment: right after funding, when expectations for traction start to rise.

Three patterns show up again and again:

1. No clear picture of the buyer. "Hospitals" is not a customer. A hospital is a lab director who loves the technology, a CFO who controls the budget, an IT team that has to approve the integration, and a value analysis committee that has to sign off. Companies that haven't mapped who decides, who pays, and who can say no end up in long, friendly conversations that never close.
2. Go-to-market gets built under pressure. When there's no plan for positioning, pricing, and outreach until launch is already underway, every decision feels rushed. Messaging gets written for investors instead of buyers. Pricing gets set by guesswork. Early customers get chosen because they said yes, not because they fit.
3. The first sales hire comes too early, or too late. Hire a full-time VP of Sales before the motion is defined, and you'll pay a high salary to someone to figure out what the founders haven't. Wait too long, and the founders end up carrying sales on top of the science, doing both at half capacity.

What buyers in this market actually need to see

Life science buyers are not impulse buyers. Sales cycles commonly run six to eighteen months. The people evaluating you often hold PhDs and MDs, and they will read your data more carefully than your pitch deck. That changes what "selling" means.

Your science earns the meeting. What earns the contract is everything around it:

• A clear answer to "why now, and why us?" in the buyer's language, not yours.
• Proof that fits their world: outcomes, workflow impact, and cost, framed for the person who has to defend the purchase internally.
• A path through their buying process, including the committees and approvals you won't see unless you ask.
• Confidence you'll still be around to support them after the contract is signed.

Build the foundation before you need it.

The companies that move fastest after the science works don't necessarily have bigger teams. They put the commercial foundation in place early, before launch pressure arrives. In practice, that means four things:

Define your first customer precisely. Pick the segment where your product solves the most painful problem and the buying process is shortest. Hospital, research lab, pharma partner, or payer: each needs a different motion, and trying to serve all of them at once spreads a small team too thin.

Map the buying committee. For your first segment, list every role that touches the decision, what each one cares about, and what would make each one say no. This is the single most useful exercise most technical teams skip.

Write positioning for the buyer, not the investor. Investors want to hear about market size and defensibility. Buyers want to know what changes for them on Monday morning. Same company, very different story.

Test the motion before you scale it. Before hiring a full sales team, prove that a repeatable process works: which messages get replies, which titles take meetings, which objections come up, and how long each stage really takes.

Where fractional support fits

This is the stage where a full-time sales leader is often premature, but doing nothing is expensive. Fractional go-to-market support gives you experienced commercial help for a defined scope and timeframe: building the playbook, running early outreach, and handing a working process to your first full-time hire when you're ready to make one.

It's not a replacement for building a team. It's how you make sure the team you eventually build walks into something that already works.

The bottom line

The science is what makes your company worth building. But in the life sciences, the market doesn't automatically reward the best technology. It rewards the technology that reaches the right buyer, with the right story, through the right process.

If your science is working and your traction isn't keeping up, that gap is solvable, and it's easier to solve now than after the next board meeting.